| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司（以下简称"公司"）于近日收到保荐机构东兴 证券股份有限公司（以下简称"东兴证券"）出具的《关于更换持续督导保荐代 表人的函》。 东兴证券作为公司 2021 年度首次公开发行股票并在创业板上市项目和 2023 年度向不特定对象发行可转换公司债券项目的持续督导保荐机构，目前正在履行 持续督导职责。东兴证券委派朱海洲先生、姚维先生作为公司保荐代表人，负责 上述项目的持续督导工作，持续督导期限至募集资金使用完毕为止。 本次变更后，公司持续督导保荐代表人为朱海洲先生、毕文国先生，持续督 导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义务结束为 止。 公司董事会对姚维先生在公司持续督导期间所做的工作表示衷心感谢！ 特此公告。 青岛百洋医药股份有 ...

经济观察网 2月24日，百洋医药股价上涨3.46%，报收24.21元，成交额2.29亿元，换手率1.78%；主力资 金净流出2899.03万元，但游资和散户资金呈净流入状态。2月25日，股价小幅回调，最新价24.14元，下 跌0.29%，成交额5660万元，当日振幅0.99%。近5日股价累计上涨1.00%，表现略强于大盘指数。 以上内容基于公开资料整理，不构成投资建议。 近期事件 融资融券方面，2月24日百洋医药获融资买入3029.56万元，融资净买入434.75万元，融资余额达4.84亿 元，占流通市值比例3.81%，处于近一年较高水平；融券余额45.03万元，处于低位。公司近期无其他重 大公告或经营事件。 ...

Group 1 - The core viewpoint of the article is that Baiyang Pharmaceutical has announced that its subsidiary, Baiyang Pharmaceutical, has received proposed selection qualifications for several drugs, which are expected to be implemented by the end of March 2026 [2] - The drugs that received proposed selection qualifications include: Nait (Nifedipine Controlled-Release Tablets), Naqi (Celecoxib Capsules), Naishu (Duloxetine Hydrochloride Enteric-Coated Capsules), and Naixin (Memantine Hydrochloride Sustained-Release Capsules) [2] - Currently, these drugs account for a small proportion of the company's revenue [2]

Core Viewpoint - Baiyang Pharmaceutical's brand DQIAO has launched a new liquid glucosamine calcium product targeting middle-aged consumers' joint and bone health management, continuing its innovation in the calcium nutrition sector [1] Group 1: Product Launch and Market Position - The new product, SJJ, is set to be released in 2025 and focuses on the health management of joints and bones for new middle-aged consumers [1] - DQIAO has maintained its position as the number one imported calcium supplement brand in China for nine consecutive years [1] - The product is currently being produced in South Korea, indicating a global production chain established by the company [1]

证券代码：301015 证券简称：百洋医药 公告编号：2026-003 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、担保进展情况 为满足日常经营资金需求，天津百洋向中国光大银行股份有限公司青岛分行（以 下简称"光大银行"）申请了综合授信额度，公司与光大银行签订了《最高额保证 合同》，为上述授信额度提供连带责任保证担保，公司对天津百洋担保的主债权最 高本金余额为 1,000 万元。 为满足日常经营资金需求，上海制药向南京银行股份有限公司上海分行（以下 简称"南京银行"）申请了综合授信额度，百洋制药与南京银行签订了《最高额保 证合同》，为上述授信额度提供连带责任保证担保，百洋制药对上海制药的担保债 权的最高本金余额为 3,000 万元。 本次担保事项在前述担保额度范围内，无需另行召开董事会及股东会审议。 本次担保前公司对天津百洋已提供且尚在担保期限内的担保余额为1,000万元； 本次担保后公司对天津百洋已提供且尚在担保期限内的担保余额为 1,000 万元， ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Group 1 - The core point of the article is that Baiyang Pharmaceutical announced the approval of two proposals at its first extraordinary shareholders' meeting in 2026, which involve joint investment with professional investment institutions and the confirmation of related transactions for 2025 and expected daily related transactions for 2026 [2] Group 2 - The first proposal approved is related to joint investment with professional investment institutions, indicating a strategic move to enhance collaboration and investment opportunities [2] - The second proposal involves the confirmation of related transactions for the year 2025 and the expected daily related transactions for 2026, which suggests ongoing operational activities and financial planning [2]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议召开时间：2026年1月15日（星期四）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年1月15日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为2026年1月15日9:15至15:00的任意时间。 2.召开地点：山东省青岛市市北区桐柏路88号1号楼青岛百洋医药股份有限 公司会议室 3.召开方式：本次股东会采用现场表决与网络投票相结合的方式召开 4.召集人：董事会 5.主持人：董事长付钢 ...

北京市天元律师事务所 关于青岛百洋医药股份有限公司 2026 年第一次临时股东会的 法律意见 京天股字（2026）第 014 号 致：青岛百洋医药股份有限公司 青岛百洋医药股份有限公司（以下简称"公司"）2026 年第一次临时股东会（以 下简称"本次股东会"）采取现场投票与网络投票相结合的方式召开，其中现场会 议于 2026 年 1 月 15 日 14:30 在山东省青岛市市北区桐柏路 88 号 1 号楼青岛百洋 医药股份有限公司会议室召开。北京市天元律师事务所（以下简称"本所"）接受 公司聘任，指派本所律师出席本次股东会并进行见证，并根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东会规则（2025 修订）》（以下简称"《股东会规则》"）以及 《青岛百洋医药股份有限公司章程》（以下简称"《公司章程》"）等有关规定，就 本次股东会的召集、召开程序、出席现场会议人员的资格、召集人资格、会议表 决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《青岛百洋医药股份有限公司第四届董 事会第四次会议决议公告》《青岛百洋医药 ...

Core Viewpoint - Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.01% and a current price of 25.31 CNY per share, reflecting a total market capitalization of 13.304 billion CNY [1] Group 1: Stock Performance - Since the beginning of the year, Baiyang Pharmaceutical's stock price has increased by 7.25%, with a 3.86% rise over the last five trading days and a 12.44% increase over the last 20 days, while it has decreased by 1.86% over the last 60 days [1] - The trading volume reached 206 million CNY, with a turnover rate of 1.52% [1] Group 2: Financial Performance - For the period from January to September 2025, Baiyang Pharmaceutical reported a revenue of 5.627 billion CNY, representing a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of 476 million CNY, down 25.67% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 1.551 billion CNY, with 1.201 billion CNY distributed over the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Baiyang Pharmaceutical is 11,100, a decrease of 40.83% from the previous period, while the average circulating shares per person increased by 68.99% to 47,194 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the newest shareholder, holding 2.9097 million shares [3]